Clinical trial NCT05418127: An Efficacy Trial in the Research Area of Gastrointestinal Health & Bloating
Official title: A Randomized, Double-blinded, Placebo-controlled, Parallel Study, to Assess the Effect of Traditionally Fermented Organic Coconut Milk Kefir on Gastrointestinal Symptoms in Healthy Adults
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Gastrointestinal Dysfunction
Lead sponsor: Coconut Goodness Food Products Inc.
Sponsor class: INDUSTRY
First posted: 2022-06-14
Enrollment: 60
Sex: ALL
Minimum age (years): 25
Maximum age (years): 54
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, double-blinded, placebo-controlled, parallel study.
Primary purpose: TREATMENT

Brief summary: A randomized, double-blinded, placebo-controlled, parallel study, to evaluate the effect of 8-week supplementation of a traditionally fermented organic coconut milk kefir compared to placebo on gastrointestinal symptoms in healthy adults.


Eligibility criteria: Inclusion Criteria:

1. Willing to participate in the study and comply with its procedures, including but not limited to consuming study product, adhering to visit schedule and e-diary/questionnaires, abstaining from products outlined in Section 5.8 of Study Protocol.
2. Able and willing to give written informed consent.
3. Adults aged between 25 to 54 years, inclusive.
4. Self-reported bloating on at least 3 occasions over the 7-day period immediately prior to enrolment (confirmed by selecting any option other than 'None' in response to the daily electronic diary Bloating question in the electronic diary questionnaire completed prior to enrolment).

Exclusion Criteria:

1. Participants who are pregnant or wish to become pregnant during the trial.
2. Participants who are lactating and/or currently breastfeeding.
3. Participants currently of childbearing potential, but not using an effective method of contraception for at least 30 days prior to dosing, as outlined below:

   1. Complete abstinence from intercourse prior to administration of the study product, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the study product in cases where participant discontinues the trial prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit).
   2. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that participant.
   3. Sexual partner(s) is/are exclusively female.
   4. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g. male condom, female diaphragm), or contraceptive pill/patch/injection/ring. The participant must be using this method for at least 30 days prior to and 2 weeks following the end of the trial.
   5. Use of any intrauterine device (IUD) or contraceptive implant. The participant must have the device inserted at least 30 days prior to the first Screening Visit, throughout the trial, and 2 weeks following the end of the trial.
4. Participants who have a history of histamine intolerance (i.e., intolerance to fermented food) or any known coconut or tree nut allergy.
5. Participants who have consumed prebiotic or probiotic supplements in the 14 days prior to screening (Visit 1).
6. Participants have consumed fermented coconut/kefir products in the 14 days prior to screening (Visit 1) and are intending to consume such products during the course of the trial.
7. Participants who have used oral antibiotics in the 90 days prior to screening (Visit 1).
8. Participants who have had gastrointestinal surgery (e.g., colectomy, gall bladder removal, gastric bypass) - appendectomy not considered an exclusionary surgery.
9. Participants who have any significant health conditions or current medications that would prevent them from fulfilling the trial requirements, put the Participant at risk or would confound the interpretation of the trial results as judged by the investigator on the basis of medical history, medication history, and routine laboratory test results.
10. Participants who cannot safety stop taking prescription medication for the duration of the trial
11. Participants may not be receiving treatment involving experimental drugs. If the Participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to screening (Visit 1).
12. Participants who have used any immunosuppressant or chemotherapy medications, including marcaptopurine, azothioprine, or methotrexate in the last 5 years.
13. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
14. Any Participant who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Primary outcomes:
measure: Change in proportion of Participants who report a change in the maximum severity of their bloating in a daily eDiary.
timeFrame: 8 weeks
Secondary outcomes:
measure: Change in mean daily severity of Abdominal Pain symptoms of Participants (as recorded in the daily e-diary Abdominal Pain question).
timeFrame: 8 weeks
measure: Change in mean daily severity of Abdominal Discomfort symptoms of Participants (as recorded in the daily e-diary Abdominal Pain question).
timeFrame: 8 weeks
measure: Change in proportion of Participants experiencing Flatulence/Gas symptoms (selecting any option other than 'None' in response to the daily e-diary Flatulence/Gas question).
timeFrame: 8 weeks
measure: Difference between product groups of self-reported symptom improvement from the Global Impression of Change Scale at end of intervention.
timeFrame: 8 weeks
Other outcomes:
measure: Change in Hs-CRP
timeFrame: 8 weeks
measure: Change in microbiome profile
timeFrame: 8 weeks
measure: Overall product satisfaction questionnaire as measured by the Overall Product Satisfaction Questionnaire
timeFrame: 8 weeks
measure: Change in quality of life assessed by the Short Form-36 (SF-36)
timeFrame: 8 weeks
measure: Change in daily performance (energy and mental clarity) assessed daily eDiary
timeFrame: 8 weeks
measure: Incidence of Adverse Events (AEs) [Safety]
timeFrame: 8 weeks
measure: Incidence of mild, moderate, and severe AEs [Safety]
timeFrame: 8 weeks
measure: Incidence of AEs by MEDRA System Organ Classification (SOC) and preferred term (PT) [Safety]
timeFrame: 8 weeks
measure: Incidence of Vital Parameter AEs [Safety]
timeFrame: 8 weeks
measure: Incidence of Serious Adverse Events (SAEs) [Safety]
timeFrame: 8 weeks
Locations:
city: Chicago
country: United States
facility: Atlantia Clinical Trials Ltd.
state: Illinois
Study officials:
affiliation: Atlantia Clinical Trials Ltd.
name: Stacey Boetto, FNP-C
role: PRINCIPAL_INVESTIGATOR
References: